title: The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Charokopou
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: H
authors.initials: H
authors.lastname: Vioix
authors.affiliation: Pharmerit International, Rotterdam, The Netherlands.
authors.forename: B G
authors.initials: BG
authors.lastname: Verheggen
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: T
authors.initials: T
authors.lastname: Bratt
authors.affiliation: AstraZeneca UK Ltd., Luton, UK.
authors.forename: D
authors.initials: D
authors.lastname: Franks